Follow
Luca Faloppi
Luca Faloppi
UOC Oncologia - Ospedale Generale Macerata - ASUR Marche AV3
Verified email at sanita.marche.it
Title
Cited by
Cited by
Year
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study
M Scartozzi, L Faloppi, G Svegliati Baroni, C Loretelli, F Piscaglia, ...
International journal of cancer 135 (5), 1247-1256, 2014
1432014
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
M Scartozzi, R Giampieri, E Maccaroni, M Del Prete, L Faloppi, ...
British journal of cancer 106 (5), 799-804, 2012
1202012
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
AC Gardini, E Scarpi, L Faloppi, M Scartozzi, N Silvestris, D Santini, ...
Oncotarget 7 (41), 67142, 2016
1032016
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
L Faloppi, M Scartozzi, M Bianconi, G Svegliati Baroni, P Toniutto, ...
BMC cancer 14, 1-8, 2014
1012014
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
M Scartozzi, M Bianconi, L Faloppi, C Loretelli, A Bittoni, M Del Prete, ...
British journal of cancer 108 (5), 1126-1132, 2013
962013
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale
AC Gardini, L Faloppi, S De Matteis, FG Foschi, N Silvestris, F Tovoli, ...
European Journal of Cancer 86, 106-114, 2017
942017
The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study
M Santoni, A Rizzo, V Mollica, MR Matrana, M Rosellini, L Faloppi, ...
Critical Reviews in Oncology/Hematology 170, 103596, 2022
912022
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
M Scartozzi, I Bearzi, A Mandolesi, R Giampieri, L Faloppi, E Galizia, ...
British journal of cancer 104 (11), 1786-1790, 2011
872011
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy
R Giampieri, E Maccaroni, A Mandolesi, M Del Prete, K Andrikou, ...
Gastric Cancer 20, 156-163, 2017
822017
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib
A Casadei Gardini, G Marisi, E Scarpi, M Scartozzi, L Faloppi, N Silvestris, ...
Expert opinion on pharmacotherapy 16 (18), 2719-2725, 2015
742015
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment
M D’Anzeo, L Faloppi, M Scartozzi, R Giampieri, M Bianconi, M Del Prete, ...
Molecules 19 (5), 6393-6406, 2014
732014
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
A Gnoni, D Santini, M Scartozzi, A Russo, A Licchetta, V Palmieri, L Lupo, ...
Expert opinion on therapeutic targets 19 (12), 1623-1635, 2015
702015
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-taylored therapeutic options
L Faloppi, M Scartozzi, E Maccaroni, MDP Paolo, R Berardi, M Del Prete, ...
Cancer treatment reviews 37 (3), 169-177, 2011
692011
Lactate dehydrogenase in hepatocellular carcinoma: something old, something new
L Faloppi, M Bianconi, R Memeo, A Casadei Gardini, R Giampieri, ...
BioMed research international 2016, 2016
632016
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management
M Scartozzi, L Faloppi, M Bianconi, R Giampieri, E Maccaroni, A Bittoni, ...
PloS one 7 (3), e32653, 2012
632012
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular …
M Scartozzi, GS Baroni, L Faloppi, MDP Paolo, C Pierantoni, R Candelari, ...
Journal of Experimental & Clinical Cancer Research 29, 1-8, 2010
592010
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management
M Del Prete, R Giampieri, F Loupakis, T Prochilo, L Salvatore, L Faloppi, ...
Oncotarget 6 (32), 33982, 2015
562015
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
L Faloppi, M Bianconi, R Giampieri, A Sobrero, R Labianca, D Ferrari, ...
Oncotarget 6 (33), 35087, 2015
502015
First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase …
A Ravaud, S Oudard, G Gravis-Mescam, E Sevin, S Zanetta, C Theodore, ...
Journal of Clinical Oncology 27 (15_suppl), 5146-5146, 2009
502009
First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase …
A Ravaud, S Oudard, G Gravis-Mescam, E Sevin, S Zanetta, C Theodore, ...
Journal of Clinical Oncology 27 (15_suppl), 5146-5146, 2009
502009
The system can't perform the operation now. Try again later.
Articles 1–20